Study protocol of LANTana: a phase Ib study to investigate epigenetic modification of somatostatin receptor-2 with ASTX727 to improve therapeutic outcome with [177Lu]Lu-DOTA-TATE in patients with metastatic neuroendocrine tumours, UK

INTRODUCTION: Suitability for peptide receptor radionuclide therapy (PRRT) for neuroendocrine neoplasia (NENs) depends on presence of somatostatin receptor-2 (SSTR2) determined by [68Ga]Ga-DOTA-peptide-positron emission tomography (PET). Some patients have low or no uptake on [68Ga]Ga-DOTA-peptide-P...

Descripción completa

Detalles Bibliográficos
Autores principales: Murphy, Ravindhi, Chander, Gurvin, Martinez, Maria, Ward, Caroline, Khan, Sairah R, Naik, Mitesh, Barwick, Tara, Aboagye, Eric, Sharma, Rohini
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10603539/
https://www.ncbi.nlm.nih.gov/pubmed/37879695
http://dx.doi.org/10.1136/bmjopen-2023-075221

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10603539/
https://www.ncbi.nlm.nih.gov/pubmed/37879695
http://dx.doi.org/10.1136/bmjopen-2023-075221

Ejemplares similares